Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 288, Issue 2 32-2, 2005, Pages

  Clarke, Deborah L ^a   Belvisi, Maria G ^a   Smith, Susan J ^a   Hardaker, Elizabeth ^a   Yacoub, Magdi H ^a   Meja, Koremu K ^a   Newton, Robert ^c   Slater, Donna M ^b   Giembycz, Mark A ^c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Airway inflammation; cAMP dependent protein kinase; Granulocyte colony stimulating factor; Human airway smooth muscle; Prostanoid receptors

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 16,16 DIMETHYLPROSTAGLANDIN E2; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; BIMATOPROST; BUTAPROST; CICAPROST; CYCLIC AMP DEPENDENT PROTEIN KINASE; FLUPROSTENOL; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; L 161982; MISOPROSTOL; ONO AE1 259; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG SELECTIVITY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TRACHEA MUSCLE;

ADOLESCENT; ADULT; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DINOPROSTONE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, PROSTAGLANDIN E; TRACHEA;

EID: 12144251393     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00313.2004     Document Type: Article

References (67)

1. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, and Metters KM. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483: 285-293, 2000.
2. Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DW, Torphy TJ, Penn RB, and Panettieri RA. Tumor necrosis factor-α-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate. Am J Respir Cell Mol Biol 23: 794-802, 2000.
3. Ammit AJ, Lazaar AL, Irani C, O'Neill GM, Gordon ND, Amrani Y, Penn RB, and Panettieri RA. Tumor necrosis factor-α-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 26: 465-474, 2002.
4. Amrani Y, Lazaar AL, and Panettieri RA. Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-κB- dependent signaling pathway that is only partially sensitive to dexamethasone. J Immunol 163: 2128-2134, 1999.
5. 2-subtype. J Biol Chem 269: 11873-11877, 1994.
6. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ, and Metcalf D. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 68: 162-166, 1986.
7. Bradley TR and Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44: 287-299, 1966.
8. Breyer RM, Bagdassarian CK, Myers SA, and Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001.
9. 2 might be mediated by increased numbers of E-prostanoid receptors. J Allergy Clin Immunol 113: 876-881, 2004.
10. 2 inhibits the release of GM-CSF. Br J Pharmacol 141: 1141-1150, 2004.
11. 2 (Abstract). Am J Respir Crit Care Med 163: A515, 2001.
12. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, and Sheldrick RL. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47: 151-168, 1994.
13. Coleman RA, Humphrey PPA, Sheldrick RL, and White BP. Gastric antisecretory prostanoids: actions at different prostanoid receptors (Abstract). Br J Pharmacol 95: 724P, 1988.
14. 2-sensitive EP-receptors. Adv Prostaglandin Thromboxane Leukot Res 17A: 467-470, 1987.
15. Coleman RA, Smith WL. and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994.
16. Collins SP and Uhler MD. Characterization of PKIγ, a novel isoform of the protein kinase inhibitor of cAMP-dependent protein kinase. J Biol Chem 272: 18169-18178, 1997.
17. Davies SP, Reddy H, Caivano M, and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
18. Day RN, Walder JA, and Maurer RA. A protein kinase inhibitor gene reduces both basal and multihormone-stimulated prolactin gene transcription. J Biol Chem 264: 431-436, 1989.
19. Dong YJ, Jones RL, and Wilson NH. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol 87: 97-107, 1986.
20. Engh RA, Girod A, Kinzel V, Huber R, and Bossemeyer D. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. J Biol Chem 271: 26157-26164, 1996.
21. Fujino H and Regan JW. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol Sci 24: 335-340, 2003.
22. 2. J Biol Chem 277: 2614-2619, 2002.
23. 2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278: 12151-12156, 2003.
24. B-receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi. Br J Pharmacol 117: 995-999, 1996.
25. Fukuroda T, Ozaki S, Ihara M, Ishikawa K, Yano M, and Nishikibe M. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol 113: 336-338, 1994.
26. Gardiner PJ. Characterization of prostanoid relaxant/inhibitory receptors (ψ) using a highly selective agonist, TR4979. Br J Pharmacol 87: 45-56, 1986.
27. Gardiner PJ. Prostanoids. In: Airway Smooth Muscle: Neurotransmitter, Amines, Lipid Mediators and Signal Transduction, edited by Raeburn D and Giembycz MA. Basel: Birkhäuser, 1995, p. 181-198.
28. Giles H, Leff P, Bolofo ML, Kelly MG, and Robertson AD. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 96: 291-300, 1989.
29. Glass DB, Cheng HC, Kemp BE, and Walsh DA. Differential and common recognition of the catalytic sites of the cGMP-dependent and cAMP-dependent protein kinases by inhibitory peptides derived from the heat-stable inhibitor protein. J Biol Chem 261: 12166-12171, 1986.
30. Gomez-Foix AM, Coats WS, Baque S, Alam T, Gerard RD, and Newgard CB. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem 267: 25129-25134, 1992.
31. Hallsworth MP, Moir LM, Lai D, and Hirst SJ. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am J Respir Crit Care Med 164: 688-697, 2001.
32. 2- Adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 132: 729-741, 2001.
33. 2 receptor. CRTH2. J Immunol 168: 981-985, 2002.
34. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193: 255-261, 2001.
35. Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, Narumiya S, and Ichikawa A. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem 268: 7759-7762, 1993.
36. Ichikawa Y, Pluznik DH, and Sachs L. In vitro control of the development of macrophages and granulocyte colonies. Proc Natl Acad Sci USA 56: 488-495, 1966.
37. Johnson SR and Knox AJ. Synthetic functions of airway smooth muscle in asthma. Trends Pharmacol Sci 18: 288-292, 1997.
38. Kageyama K and Suda T. Urocortin-related peptides increase interleukin-6 output via cyclic adenosine 5′-monophosphate-dependent pathways in A7r5 aortic smooth muscle cells. Endocrinology 144: 2234-2241, 2003.
39. Kawasaki ES, Ladner MB, Wang AM, Van Arsdell J, Warren MK, Coyne MY, Schweickart VL, Lee MT, Wilson KJ, Boosman A, Stanley ER, Ralph P, and Mark DF. Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1). Science 230: 291-296, 1985.
40. Keery RJ and Lumley P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol 94: 745-754, 1988.
41. Kennedy I, Coleman RA, Humphrey PP, Levy GP, and Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins 24: 667-689, 1982.
42. Kobayashi T and Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 68-69: 557-573, 2002.
43. Laporte JD, Moore PE, Lahiri T, Schwartzman IN, Panettieri RA, and Shore SA. p38 MAP kinase regulates IL-1β responses in cultured airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279: L932-L941, 2000.
44. 2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy. Am J Respir Cell Mol Biol 24: 44-48, 2001.
45. Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, and Vadas MA. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78: 1220-1228, 1986.
46. Lum H, Jaffe HA, Schulz IT, Masood A, RayChaudhury A, and Green RD. Expression of PKA inhibitor (PKI) gene abolishes cAMP-mediated protection to endothelial barrier dysfunction. Am J Physiol Cell Physiol 277: C580-C588, 1999.
47. Lydford SJ, McKechnie KC, and Dougall IG. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol 117:13-20, 1996.
48. 2. Mol Pharmacol 60: 36-41, 2001.
49. 2: a comparison with H-89. J Pharmacol Exp Ther 309: 833-844, 2004.
50. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67: 257-267, 1986.
51. 2 receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 69: 169-177, 2003.
52. Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H, and Ono M. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319: 415-418, 1986.
53. Narumiya S, Sugimoto Y, and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226, 1999.
54. 2-agonist. Cardiovasc Drug Rev 11: 165-179, 1993.
55. 4 subtype. FEBS Lett 364: 339-341, 1995.
56. Olsen SR and Uhler MD. Isolation and characterization of cDNA clones for an inhibitor protein of cAMP-dependent protein kinase. J Biol Chem 266: 11158-11162, 1991.
57. B receptors. J Biochem (Tokyo) 121: 440-447, 1997.
58. 2-agonists and corticosteroids. FASEB J 15: 261-269, 2001.
59. Scarpetta MA and Uhler MD. Evidence for two additional isoforms of the endogenous protein kinase inhibitor of cAMP-dependent protein kinase in mouse. J Biol Chem 268: 10927-10931, 1993.
60. Schild HO. pAx and competitive drug antagonism. Br J Pharmacol Chemother 4: 277-280, 1949.
61. Sturzebecher S, Haberey M, Muller B, Schillinger E, Schroder G, Skuballa W, Stock G, Vorbruggen H, and Witt W. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins 31: 95-109, 1986.
62. 2 receptor using structurally different antagonists. Eur J Pharmacol 152: 311-319, 1988.
63. Takio K, Wade RD, Smith SB, Krebs EG, Walsh KA, and Titani K. Guanosine cyclic 3′,5′-phosphate dependent protein kinase, a chimeric protein homologous with two separate protein families. Biochemistry 23: 4207-4218, 1984.
64. Tsuboi K, Sugimoto Y, and Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Me;diat 68-69: 535-556, 2002.
65. Wong GG, Witek JS, Temple PA, Wilkens KM, Leary AC, Luxenberg DP, Jones SS, Brown EL, Kay RM, Orr EC, Shoemaker C, Gold D, Kaufman R, Hewick RM, Wang EA, and Clarke SC. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228: 810-815, 1985.
66. 2 receptor antagonist. Biochem Pharmacol 50: 1731-1733, 1995.
67. 4, differentially modulate TNFα and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem iophys Res Commun 278: 224-228, 2000.